Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex Mas Monteys

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
HGG Advances|October 20, 2022
Haplotyping SNPs for allele-specific gene editing of the expanded huntingtin allele using long-read sequencingLi Fang, Alex Mas Monteys, Alexandra Dürr, et al.
Nature|February 2, 2022
Author Correction: Regulated control of gene therapies by drug-induced splicingAlex Mas Monteys, Amiel A Hundley, Paul T Ranum, et al.
Nature|July 29, 2021
Regulated control of gene therapies by drug-induced splicingAlex Mas Monteys, Amiel A Hundley, Paul T Ranum, et al.
Nucleic Acids Research|October 22, 2014
Single nucleotide seed modification restores in vivo tolerability of a toxic artificial miRNA sequence in the mouse brainAlex Mas Monteys, Ryan M Spengler, Brett D Dufour, et al.
Molecular Endocrinology (Baltimore, Md.)|March 4, 2010
The transcription factor ATF4 promotes skeletal myofiber atrophy during fastingScott M Ebert, Alex Mas Monteys, Daniel K Fox, et al.
Biorxiv : the Preprint Server for Biology|February 14, 2024
AAV-based delivery of RNAi targeting Ataxin-2 improves survival, strength, and pathology in mouse models of rapidly and slowly progressive sporadic ALSDefne A Amado, Ashley B Robbins, Alicia R Smith, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 10, 2008
Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAiJodi L McBride, Ryan L Boudreau, Scott Q Harper, et al.
Nature Communications|October 23, 2025
Author Correction: AAV-based delivery of RNAi targeting ataxin-2 improves survival and pathology in TDP-43 miceDefne A Amado, Ashley B Robbins, Katherine R Whiteman, et al.
Nature Communications|June 25, 2025
AAV-based delivery of RNAi targeting ataxin-2 improves survival and pathology in TDP-43 miceDefne A Amado, Ashley B Robbins, Katherine R Whiteman, et al.
Nature Communications|March 4, 2022
An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusionCaroline Gubser Keller, Youngah Shin, Alex Mas Monteys, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
HGG Advances|October 20, 2022
Haplotyping SNPs for allele-specific gene editing of the expanded huntingtin allele using long-read sequencingLi Fang, Alex Mas Monteys, Alexandra Dürr, et al.
Nature|February 2, 2022
Author Correction: Regulated control of gene therapies by drug-induced splicingAlex Mas Monteys, Amiel A Hundley, Paul T Ranum, et al.
Nature|July 29, 2021
Regulated control of gene therapies by drug-induced splicingAlex Mas Monteys, Amiel A Hundley, Paul T Ranum, et al.
Nucleic Acids Research|October 22, 2014
Single nucleotide seed modification restores in vivo tolerability of a toxic artificial miRNA sequence in the mouse brainAlex Mas Monteys, Ryan M Spengler, Brett D Dufour, et al.
Molecular Endocrinology (Baltimore, Md.)|March 4, 2010
The transcription factor ATF4 promotes skeletal myofiber atrophy during fastingScott M Ebert, Alex Mas Monteys, Daniel K Fox, et al.
Biorxiv : the Preprint Server for Biology|February 14, 2024
AAV-based delivery of RNAi targeting Ataxin-2 improves survival, strength, and pathology in mouse models of rapidly and slowly progressive sporadic ALSDefne A Amado, Ashley B Robbins, Alicia R Smith, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 10, 2008
Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAiJodi L McBride, Ryan L Boudreau, Scott Q Harper, et al.
Nature Communications|October 23, 2025
Author Correction: AAV-based delivery of RNAi targeting ataxin-2 improves survival and pathology in TDP-43 miceDefne A Amado, Ashley B Robbins, Katherine R Whiteman, et al.
Nature Communications|June 25, 2025
AAV-based delivery of RNAi targeting ataxin-2 improves survival and pathology in TDP-43 miceDefne A Amado, Ashley B Robbins, Katherine R Whiteman, et al.
Nature Communications|March 4, 2022
An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusionCaroline Gubser Keller, Youngah Shin, Alex Mas Monteys, et al.
Pageof 3